Hikma Pharmaceuticals (HIK) Ordinary GBP 0.10

Sell:1,342.50pBuy:1,343.50pPrice increased18.50p (1.40%)

FTSE 250:Price increased2.01%
Market closed |
Prices delayed by at least 15 minutes

Sell:1,342.50p
Buy:1,343.50p
Change:Price increased18.50p (1.40%)
Market closed |
Prices delayed by at least 15 minutes

Sell:1,342.50p
Buy:1,343.50p
Change:Price increased18.50p (1.40%)
Market closed |
Prices delayed by at least 15 minutes

Company Information

About this company

Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and non-licensed pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. It supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). It supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. It supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.

Key people

Said Samih Darwazah
Executive Chairman of the Board, Chief Executive Officer
Helen Middlemist
Company Secretary
Ali K. Al-Husry
Non-Executive Director
Laura Balan
Non-Executive Independent Director - Workforce Engagement
Cynthia L. Flowers
Non-Executive Independent Director
Victoria Mary Hull
Senior Non-Executive Independent Director
Douglas Malcolm Hurt
Non-Executive Independent Director
Mazen Samih Talib Darwazah
Executive Vice Chairman of the Board, President of MENA
Khalid Nabilsi
Chief Financial Officer, Executive Director
Hussein Arkhagha
Chief People Officer
Hafrun Fridriksdottir
Executive Vice President - Hikma Rx and Global Head of R&D
Susan Ringdal
Executive Vice President - Strategic Planning and Global Affairs
Bassam Wael Roshdi Kanaan
Chief Financial Officer, Executive Vice President
Julie Hill
Senior Vice President - Corporate Quality Compliance and Health and Safety
Sam Park
Group General Counsel
Click to see more

Key facts

  • Shares in issue
    230.58m
  • EPIC
    HIK
  • ISIN
    GB00B0LCW083
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    £2.89bn
  • Employees
    9,603
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index, Britain-FTSE250-Index, FTSE 100 Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.